No, please select all boxes corresponding to violations of any inclusion/ exclusion criteria - Inclusion Criteria
CL Item
Male or female between the ages of 18 and 64 years inclusive. (1)
CL Item
Male subjects, if female partner not using an acceptable method of contraception, must agree to use one of the contraception methods listed in Section 8.1.2. This criterion must be followed from the time of the first dose of study medication until one month post-last dose. (3)
CL Item
BMI within the range 18.8 – 35.0 kg/m2 (inclusive). (4)
CL Item
Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. (5)
CL Item
Subject currently meets the diagnosis for MDD (without psychotic features), single episode or recurrent, as defined in the DSM-IV-TR, diagnosed with SCID-CT (Structural Clinical Interview for DSM-IV Axis I disorders – Clinical Trials Version) as assessed* by a physician with adequate training in psychiatry. (6)
CL Item
Subject must, in the investigator’s opinion based on clinical history, have met DSM IV-TR criteria for their current major depressive episode for at least 4 weeks but for no greater than 24 months. (7)
CL Item
Subject has an independent rater HAMD17 total score ≥24, that is within 10% of the computerised HAMD17 total score, at the baseline assessment. If scores are not within 10% the independent rater or principal investigator, physician from CRS and GSK medical monitor must agree that subject is suitable for inclusion in the study. (8)
CL Item
Non-smoker or smokers (< 20 cigarettes per day). (9)
CL Item
A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.]; Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until one month post-last dose = 2. A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.]; Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until one month post-last dose (2)
CL Item
Subject must read and write at a level sufficient to complete study-related assessments. (10)
No, please select all boxes corresponding to violations of any inclusion/ exclusion criteria - Exclusion Criteria
CL Item
Subjects has: Symptoms of the presenting illness which are better accounted for by another diagnosis*; or A current DSM-IV-TR Axis I diagnosis of Dementia; or Antisocial or Borderline Personality Disorder or other current DSM-IV-TR Axis II diagnosis that would suggest non-responsiveness to pharmacotherapy or non- compliance with the protocol; or A current (or within six months prior to the Screening visit) diagnosis of anorexia nervosa or bulimia; or A lifetime history of Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder. (1)
CL Item
Subjects who, in the investigator’s judgement, pose a homicidal or serious suicidal risk, have made a suicide attempt within 6 months preceding screening or who have ever been homicidal. (2)
CL Item
Subject has initiated psychotherapy within one month prior to the Screening visit, or plans to initiate psychotherapy during the trial. Subjects who present with their current MDD diagnosis despite longer term psychotherapy (i.e., greater than three months prior to the Screening visit) and who agree to maintain the same therapy schedule during the trial may be included. (3)
CL Item
Subject has received vagus nerve stimulation, electroconvulsive therapy, or transcranial magnetic stimulation within the six months prior to the Screening visit. (4)
CL Item
Subject has previously failed an adequate therapeutic course of pharmacotherapy for MDD (e.g., for ≥ 4 weeks) from two different classes of antidepressants. (5)
CL Item
Subject has an unstable medical disorder or a disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GSK163090 or may pose a safety concern, or interfere with the accurate assessment of safety or efficacy. (6)
CL Item
The subject has a past history of drug abuse or dependence according to DSM-IV TR criteria within the past 12 months or has tested positive for urine drugs of abuse at pre-study screening except as detailed in Section 9.1.1. (7)
CL Item
Abuse of alcohol. To determine if a subject is abusing alcohol investigator will consider: average weekly intake of alcohol, score achieved on Alcohol Use Disorders Identification Test (AUDIT –C, Appendix 8 ) and results from laboratory assessments (in particular any abnormalities to AST: ALT ratio, GGT and MCV). (8)
CL Item
The subject has a past history of serotonin syndrome or in the investigator’s judgement, a history of clinical significant intolerance of SSRIs. (9)
CL Item
Subjects with a history of migraine headaches that respond to treatment with triptan medication. (10)
CL Item
The subject has a history of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (excluding febrile seizure). (11)
CL Item
A positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening. (12)
CL Item
The subject is currently participating in another clinical study in which the subject is or will be exposed to an investigational or non-investigational drug or device, or has done so within the preceding month for studies unrelated to the current illness, or six months for studies related to MDD. (13)
CL Item
The subject has a screening ECG with a QTc value of >450msec and or a PR interval outside the range 110 to 220msec or an ECG that is not suitable for QT measurements (e.g poorly defined termination of the T-wave). (14)
CL Item
Any cardiac condition or ECG evidence that the investigator feels may predispose the subject to ischemia or arrhythmia or any ECG abnormality that, in the investigator’s judgment, may pose a potential safety concern. (15)
CL Item
The subject has a systolic blood pressure (SBP) ≥160mmHg or a diastolic blood pressure (DBP) ≥ 100 mmHg verified by repeated measurement at the Screening or Randomization visit. (16)
CL Item
The subject has any liver function enzyme (ALT, AST, ALP or GGT) elevated > 2 times, or total or direct bilirubin>1.5 times (unless consistent with presumed or diagnosed Gilbert’s disease), above the reference range at pre-study screening that remains elevated with a repeat LFT. (17)
CL Item
Subjects who are not euthyroid based on lab results at the screening visit. Subjects maintained on thyroid medication must be euthyroid for a period of at least six months prior to the screen visit. (18)
CL Item
Subject has any laboratory abnormality that in the investigator’s judgement is considered to be clinically significant and could potentially affect subject safety or study outcome. (19)
CL Item
Subject is female and has a positive Human Chorionic Gonadotropin (HCG) pregnancy test at screen visit, a positive urine dipstick test at randomization, or who is lactating or planning to become pregnant within 4 weeks following the last dose of study medication. (20)
CL Item
Subject has received depot antipsychotics within the 12 weeks before screening. (21)
CL Item
Subject has taken a regular course of other psychoactive drugs within the two weeks (22)
CL Item
Subject has taken other (non-psychoactive) prescription, non-prescription, dietary, or herbal products that are potent or moderate inducers and/or inhibitors of the cytochrome P450 3A4 pathway for 2 weeks (or 5 half lives, whichever is longer) prior to the Randomization visit. (23)
CL Item
Subject has taken other (non-psychoactive) prescription, non-prescription, dietary, or herbal products metabolized via the cytochrome P450 3A4 pathway with a narrow therapeutic index within 2 weeks (or 5 half-lives, whichever is longer) prior to the Randomization visit. (24)
CL Item
Subject has taken other (non-psychoactive) prescription, non-prescription that are inhibitors of the P-glycoprotein for 2 weeks (or 5 half lives, whichever is longer) prior to the Randomization visit. (25)
CL Item
Use of monoamine oxidase inhibitors (MAOI) and linezolid (antibiotic) for 1 month prior to first dose of study medication. (26)
CL Item
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. (27)
CL Item
prior to the Screening Visit (except as discussed and permitted in section 9.1.1): All antidepressants including SSRIs (with the exception of fluoxetine, which requires 5 weeks), Long acting benzodiazepines, other psychoactive medications (including psychoactive herbal treatments, e.g., St. John’s Wort, SAM-E), Lithium, other mood stabilizers (including anticonvulsants) and oral antipsychotics, Opiates (including tramadol), hypnotics, and all other sedatives (including sedating antihistamines if they are used for their sedating and/or hypnotic properties) (prior to the Screening Visit (except as discussed and permitted in section 9.1.1): All antidepressants including SSRIs (with the exception of fluoxetine, which requires 5 weeks), Long acting benzodiazepines, other psychoactive medications (including psychoactive herbal treatments, e.g., St. John’s Wort, SAM-E), Lithium, other mood stabilizers (including anticonvulsants) and oral antipsychotics, Opiates (including tramadol), hypnotics, and all other sedatives (including sedating antihistamines if they are used for their sedating and/or hypnotic properties))